Retention of a Tricyclic Amine Analyzed with ELSD- AppNote
August 18, 2021
/
/
/
/
/
Memantine Hydrochloride, a Tricyclic Amine
As this compound lacks Chromophores, it typically requires Derivitization for use in UV detection. In this Method, we retain excellent peak shape without the need for these pre-column derivatization steps.
This compound can also cause issues with Peak Tailing in typical Reversed Phase Columns due to the strong adsorption of residual Silanols. RSD values (less than 0.4%) demonstrate the consistent and reliable Retention.
Column: Cogent Diamond Hydride™, 4μm, 100Å.
Catalog No.: 70000-10P
Dimensions: 4.6mm x 100mm
Mobile Phase: 95% Acetonitrile / 5% DI Water 10 mM Ammonium Formate
Injection vol.: 1µL
Flow rate: 1.0mL / minute.
Detection: ELSD, Gain: 12, Temperature: 50°C, Nitrogen: 3.5 bar.
Sample Preparation: 1.0mg / mL Mermantine HCL in DI Water.
Notes: Persistent activation of the N-methyl-D-aspartate (NMDA) receptors in the central nervous system triggered by glutamate is believed to cause some of the Alzheimer's disease symptoms. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and stimulation, being offered as a treatment for Alzheimer's dementia.
As this compound lacks Chromophores, it typically requires Derivitization for use in UV detection. In this Method, we retain excellent peak shape without the need for these pre-column derivatization steps.
This compound can also cause issues with Peak Tailing in typical Reversed Phase Columns due to the strong adsorption of residual Silanols. RSD values (less than 0.4%) demonstrate the consistent and reliable Retention.
Peak:
Memantine HCl
Column: Cogent Diamond Hydride™, 4μm, 100Å.
Catalog No.: 70000-10P
Dimensions: 4.6mm x 100mm
Mobile Phase: 95% Acetonitrile / 5% DI Water 10 mM Ammonium Formate
Injection vol.: 1µL
Flow rate: 1.0mL / minute.
Detection: ELSD, Gain: 12, Temperature: 50°C, Nitrogen: 3.5 bar.
Sample Preparation: 1.0mg / mL Mermantine HCL in DI Water.
Notes: Persistent activation of the N-methyl-D-aspartate (NMDA) receptors in the central nervous system triggered by glutamate is believed to cause some of the Alzheimer's disease symptoms. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and stimulation, being offered as a treatment for Alzheimer's dementia.